NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
5/8 — Partial
APTENSIO XR (methylphenidate hydrochloride) by Teva is (cns) stimulant. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APTENSIO XR is an extended-release oral capsule formulation of methylphenidate hydrochloride, a CNS stimulant approved in 2015 for ADHD. The exact mechanism of therapeutic action in ADHD remains unknown, though it functions as a stimulant to modulate central nervous system activity. It is indicated for attention-deficit/hyperactivity disorder in pediatric and adult populations.
$0.044BPart D
PeakProduct is in peak lifecycle phase with modest Part D spending, indicating mature market positioning with a stable but not rapidly expanding commercial footprint.
Mechanism of Action
(CNS) stimulant. The mode of therapeutic action in ADHD is not known.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Started Apr 2019
60 enrolled
Attention Deficit Hyperactivity DisorderGeneralized Anxiety DisorderSocial Anxiety Disorder+2 more
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
Started Apr 2011
299 enrolled
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Started Nov 2010
725 enrolled
Attention Deficit/Hyperactivity Disorder
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Started Jul 2009
357 enrolled
Attention Deficit Disorder With Hyperactivity
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
Started Jan 2008
33 enrolled
Prostatic NeoplasmsFatigue
Worked on APTENSIO XR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.